Table 1 Demographic and clinical characteristics of DIP patients with normal and abnormal DAT‐SPECT.

From: Gait abnormalities and non-motor symptoms predict abnormal dopaminergic imaging in presumed drug-induced Parkinsonism

 

Normal DAT‐SPECT n = 22/34 (65%)

Abnormal DAT‐SPECT n = 12/34 (35%)

p value

Age, years

64.1 (6.8)

65.3 (8.1)

0.671

Sex, n (%) male

21 (95%)

11 (92%)

0.654

Race/ethnicity, n (%) white

19 (86%)

9 (75%)

0.406

Diagnosis, n (%)

 Bipolar disorder

8 (36%)

3 (25%)

0.151

 Depression

4 (18%)

4 (33%)

 Post-traumatic stress disorder

5 (23%)

2 (17%)

 Schizophrenia

4 (18%)

0

 Schizoaffective disorder

0

1 (8%)

 Other psychoses

0

2 (17%)

 Epilepsy

1 (5%)

0

Psychosis, n (%)

6 (27%)

2 (17%)

0.681

Dose, CPZ equivalents, mg

308.3 (164.8)

152.5 (91.6)

0.001

DAT interfering drug, %

11 (50%)

8 (67%)

0.350

UPDRS-Part III

14.5 (7.0)

19.3 (6.0)

0.069

NMSQ total

11.4 (6.8)

16.5 (5.7)

0.033

RBDSQ total

6.1 (3.2)

7.8 (3.6)

0.175

UPSIT percentile

46.2 (23.4)

27.6 (22.1)

0.031

  1. Bold values indicates statistical significant p < 0.05.
  2. Group comparisons were assessed using chi‐square analysis and Fisher’s exact test for categorical variables, independent‐sample t-tests for normally distributed continuous variables, and Wilcoxon rank-sum for non-normally distributed continuous variables. Chlorpromazine equivalents were calculated for 31 of 34 participants.
  3. Data are mean (standard deviation) unless otherwise noted.
Back to article page